Russian scientists have identified a novel molecule with the potential to combat sepsis,a life-threatening condition affecting an estimated 1.7 million adults in the U.S. annually, and responsible for at least 250,000 deaths each year. Derived from the marine bacterium Kangiella japonica, the newly discovered compound appears to protect cells without triggering the perilous inflammatory response frequently enough associated with sepsis treatment. Researchers at the Far Eastern Branch of the russian Academy of Sciences’ Institute of Biochemistry say the molecule coudl pave the way for innovative therapies against this devastating medical challenge.
Scientists at the Far Eastern Branch of the Russian Academy of Sciences’ Institute of Biochemistry have discovered a novel molecule, derived from the marine bacterium Kangiella japonica, that demonstrates a significant ability to protect human cells from sepsis, according to a recent announcement by the research team via ТАСС Наука.
A Marine Molecule with Unprecedented Immune Properties
The newly identified molecule, known as LPS, differs substantially from the lipopolysaccharide found in Escherichia coli (E. coli) bacteria, researchers explained.
Unlike traditional LPS, this new molecule does not trigger a severe inflammatory response. It also exhibits the ability to neutralize the toxic effects of pathogenic bacterial molecules, and helps to reduce the production of pro-inflammatory cytokines – proteins that can worsen inflammation. Furthermore, the molecule inhibits the activation of caspase-4, an enzyme crucial in the cascade of events leading to sepsis.
These combined properties position the new molecule as a promising candidate for the development of innovative anti-sepsis therapies. Sepsis is a life-threatening condition that arises when the body’s response to an infection spirals out of control, leading to tissue damage, organ failure, and potentially death.
Distinct Fatty Composition and Potential Therapeutic Effect
According to data from the Institute, the fatty compound structure of this LPS contains fewer fatty acids compared to similar molecules found in pathogenic bacteria. This structural difference allows the molecule to bind to immune receptors without causing significant inflammation, suppress overreactions of the immune system, and reduce the risk of severe complications like septic shock.
The unique structure also paves the way for developing new anti-inflammatory drugs. Researchers found the molecule can effectively dampen the immune system’s response, potentially preventing the dangerous overreaction that characterizes severe infections.
Scientists believe this discovery could serve as a foundation for developing anti-inflammatory drugs targeting conditions caused by an overactive response to bacterial toxins, including sepsis, septic shock, and acute infections caused by potent bacterial pathogens. This research represents a potentially significant step forward in addressing a global health challenge, as sepsis affects millions of people worldwide each year.
